Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine

E. V. Kataeva; Катаева Е. В.; A. K. Golenkov; Голенков А. К.; E. V. Trifonova; Трифонова Е. В.; G. A. Dudina; Дудина Г. А.; T. A. Mitina; Митина Т. А.; L. L. Vysotskaya; Высоцкая Л. Л.; T. D. Lutskaya; Луцкая Т. Д.; I. V. Buravtsova; Буравцова И. В.; R. V. Gorenkov; Горенков Р. В.; Yu. Yu. Chuksina; Чуксина Ю. Ю.; V. V. Yazdovskiy; Яздовский В. В.

doi:10.17650/1818-8346-2011-6-2-4-7

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine

Authors: Kataeva E.V.¹, Golenkov A.K.¹, Trifonova E.V.¹, Dudina G.A.¹, Mitina T.A.¹, Vysotskaya L.L.¹, Lutskaya T.D.¹, Buravtsova I.V.¹, Gorenkov R.V.¹, Chuksina Y.Y.¹, Yazdovskiy V.V.¹
Affiliations:
1. M.F. Vladimirsky Moscow Regional Research Clinical Institute
Issue: Vol 6, No 2 (2011)
Pages: 4-7
Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
Published: 23.05.2011
URL: https://oncohematology.abvpress.ru/ongm/article/view/95
DOI: https://doi.org/10.17650/1818-8346-2011-6-2-4-7
ID: 95

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

In present study the immediate and long-term therapy results of 14 patients with refractory chronic lymphocytic leukemia (CLL) are analyzed. Treatment program included alemtuzumab alone or in combination with fludarabine.